Skip to main content
. Author manuscript; available in PMC: 2020 Feb 15.
Published in final edited form as: Clin Cancer Res. 2018 Oct 10;25(4):1147–1155. doi: 10.1158/1078-0432.CCR-18-2244

Figure 1.

Figure 1.

Nongenetic risk factors that may predispose patients to developing adverse events following cisplatin-based therapy. Where relevant, risk factors are denoted as being either continuous or categorical variables based on how they were examined for association with the given toxicity.